SVT MCHo
Alternative Names: SVT-MCHo; SVT-MCHo (1-10)Latest Information Update: 04 Feb 2021
At a glance
- Originator Servatus Biopharmaceuticals
- Class Antipsoriatics; Antirheumatics; Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Psoriasis; Rheumatoid arthritis
Most Recent Events
- 03 Feb 2021 Servatus Biopharmaceuticals has patent covering alterations for improvement of protein drugs (Servatus Biopharmaceuticals website, February 2021)
- 03 Feb 2021 Preclinical trials in Psoriasis in Australia (Servatus Biopharmaceuticals pipeline, February 2021)
- 03 Feb 2021 Preclinical trials in Rheumatoid arthritis in Australia (Servatus Biopharmaceuticals pipeline, February 2021)